A total of 100 adults with ALL in first CR received melphalan (110 mg/m 2 ) with TBI followed by autologous marrow (n ¼ 35) or single-agent melphalan (200 mg/m 2 ) followed by autologous blood stem cells (n ¼ 65). After adequate hematologic recovery, maintenance chemotherapy with 6-mercaptopurine, methotrexate and vincristine-prednisone was administered for 2 years. Six patients, all TBI recipients (P ¼ 0.001), died of toxicity. In total 70 patients received 6-mercaptopurine, 53 received methotrexate and 40 received vincristine-prednisone. The cumulative incidence of relapse at 7 years was 45%. The 7-year probabilities of disease-free survival (DFS) and overall survival were 45 and 48%. Age 30 years, 44 weeks to attain remission, and karyotypes t(4;11) and t(9;22) were associated with adverse outcome. Patients with 0 (standard risk), 1 (intermediate risk), and 2-3 (high risk) adverse features had 7-year cumulative incidences of relapse of 19, 53 and 82% (Po0.0001), and 7-year DFS probabilities of 73, 36 and 7% (Po0.0001). The 7-year probabilities of DFS for patients receiving 0, 1, 2 and 3 maintenance chemotherapy agents were 15, 29, 58 and 61% (Po0.0001). Maintenance chemotherapy intensity was an independent determinant of outcome in Cox analysis. Maintenance chemotherapy after autotransplantation reduces relapse and improves outcome in adult patients with ALL.
Introduction
We have shown 1, 2 that results of autologous hematopoietic stem cell transplantation (HSCT) in adult ALL [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] can be improved by administering post transplant maintenance chemotherapy with 6-mercaptopurine (6-MP), methotrexate and vincristine-prednisone. A recent review of autologous HSCT in ALL 15 suggested that the value of autotransplantation is likely to be underestimated in ALL. That conclusion is in keeping with the findings of a registry report that showed that survival after autologous HSCT was comparable to that after allogeneic HSCT from unrelated donors in ALL patients. 16 However, a major recent cooperative ALL study 17 found autotransplantation to be inferior to chemotherapy. There was no provision for maintenance therapy after autologous HSCT in this study. As conventional autologous HSCT is unlikely to be explored in ALL in future studies after these negative findings, we undertook a final review of our 20-year experience of post-autograft maintenance chemotherapy in ALL.
Patients and methods
All consecutive patients over the age of 15 who were autografted for ALL in first CR between July 1984 and February 2003 at the Leukaemia Unit of the Royal Marsden Hospital were included. All data were gathered and updated prospectively on a continuous basis. 18 Transplantation was performed as part of a standard treatment approach to adult ALL. Any research protocols that patients participated in during the course of the treatment were approved by the Ethics Committee of the Royal Marsden Hospital. All patients gave informed consent for transplantation. Table 1 shows patient characteristics.
The first 35 patients were conditioned with 110 mg/m 2 melphalan and single-fraction TBI between 1984 and 1992, and received marrow. During this period, patients with HLA-identical siblings underwent allogeneic HSCT in first remission. From 1993 onward, autologous HSCT using blood stem cells with 200 mg/m 2 single-agent melphalan conditioning was performed irrespective of the availability of HLA-matched siblings. The intention was to perform a low-morbidity autograft-reserving a salvage allograft in second remission for relapsing patients ('sequential highdose therapy'). Exceptions to sequential high-dose therapy included patients taking 48 weeks to attain CR, those with central nervous system (CNS) disease at presentation, and those with Ph þ disease. These patients underwent allogeneic HSCT in first remission if an HLA-matched sibling donor was available. Patients with t(9;22) were transplanted from unrelated donors (if available) in the absence of a matched sibling donor. However, t(9;22) was not a bar to a marrow autograft originally (n ¼ 4) or to a blood cell autograft if no donor was available (n ¼ 2). Patients with lymphoid blast crisis of CML, biphenotypic disease and mature B-cell disease (FAB type L3) were treated differently and were excluded.
The first 77 (35 marrow, 42 blood) of these 100 patients have been reported earlier, 1 as have been all the 65 blood recipients. 2 However, this is the only composite report of all patients with mature follow-up. Central nervous system prophylaxis Patients treated with melphalan-TBI received an additional 800 cGy cranial (no CNS disease) or craniospinal (CNS disease) irradiation in five daily fractions the week before TBI. Patients treated with melphalan alone received 2400 cGy cranial irradiation in 15 fractions after hematologic recovery from intensification or phase II induction and before stem cell apheresis. No patient received testicular irradiation.
Induction chemotherapy
Patients without CNS disease received six injections of 15 mg methotrexate intrathecally over the treatment period prior to the transplant, and those with CNS disease received triple intrathecal chemotherapy with 15 mg methotrexate, 30 mg cytarabine and 100 mg hydrocortisone until six consecutive spinal fluid samples were free of disease. No intrathecal chemotherapy was administered post transplant based upon our observation that isolated post transplant CNS recurrence is rare. 19 Stem cell collection and infusion BM was harvested from the posterior iliac crests under general anesthesia 6-8 weeks after completion of intensification therapy. Seven patients received marrow that was purged in vitro with Campath-1M. 20 The first seven blood stem cell recipients received G-CSF (filgrastim) at the dose of 125 mg/m 2 s.c. twice a day for 7 days, and underwent leukapheresis on days 5-8 (4 consecutive days). They also had back-up autologous marrow collected (which was not used). The next 58 patients received 12-16 mg/kg filgrastim s.c. once daily on days 1-4, and stem cells were harvested by apheresis on days 4 and 5. Cells were cryopreserved with 10% DMSO using a controlled-rate freezer, and were stored in the vapor phase of liquid nitrogen. The cells were rapidly thawed in a water bath at 37 1C by the bedside and infused within 2 weeks of collection. 
High-dose therapy and transplantation
The conditioning regimen for the 35 marrow recipients was 110 mg/m 2 melphalan on day À1 and single-fraction TBI on day 0, and 950 (n ¼ 2), 1050 (n ¼ 31) or 1150 cGy (n ¼ 2). TBI was delivered from opposed 60 Co sources at a low dose rate (4 cGy/min). Autologous marrow was infused on day 0. The 65 blood stem cell recipients were administered a single dose of 200 mg/m 2 melphalan with hydration on day À1. All cryopreserved cells (excluding back-up marrow) were infused on day 0; 24 h after the administration of melphalan. No myeloid growth factors were administered post transplant.
Supportive care
All patients were treated in protective isolation with positive-pressure ventilation. Blood products transfused were not screened for CMV Ab in CMV-seropositive patients. Antibiotic prophylaxis and therapy varied in accordance with prevalent practices and protocols. Irradiated random platelets were transfused to maintain the platelet count at 20 Â 10 9 /l, and packed cells to maintain the Hb at 100 g/l.
Maintenance chemotherapy Daily 6-MP was started when the leukocytes reached 3 Â 10 9 /l and the platelets 100 Â 10 9 /l, and was continued for 2 years. Commencement of chemotherapy was delayed only by inadequate hematologic recovery, relapse or ongoing medical problems (for example, active infection) that could be exacerbated by starting chemotherapy. Therapy was started at the dose of 25 mg, and this was increased weekly or fortnightly in 25-50 mg steps. Weekly oral methotrexate at the dose of 5 mg (increasing in 2.5-5 mg steps) was added when the dose of 6-MP reached 75 mg. Until 1995, monthly vincristine (1.4 mg/m 2 ; maximum 2 mg) with prednisone (40 mg/m 2 daily for a week) was administered to patients who could not tolerate myelosuppressive chemotherapy with 6-MP and methotrexate. After 1995, this combination was administered routinely to all patients. The target doses of 6-MP and methotrexate were 80 mg/m 2 daily and 20 mg/m 2 weekly, respectively. Patients were evaluated at least once every 4 weeks while on therapy, and drug doses adjusted to maintain the absolute neutrophil count over 1 Â 10 9 /l. All maintenance chemotherapy was discontinued 2 years after starting 6-MP.
Patients received folic acid supplementation, acyclovir to prevent Varicella zoster reactivation, and pneumocystis prophylaxis with oral trimethoprim-sulfamethoxazole (if onX50% of the target 6-MP dose) or aerosolized pentamidine (if on o50% of target 6-MP dose) while on maintenance chemotherapy.
Statistical analysis
The probabilities of disease-free survival (DFS) and overall survival (OS) were estimated by the Kaplan-Meier method, and compared using the log-rank test. The cumulative incidence of relapse was estimated using transplant-related deaths (n ¼ 6) and the following six occurrences as competing risks: three myelodysplastic syndromes (MDS), one homicide, one myocardial infarction and one car accident. The significance of differences in relapse was calculated using the likelihood-ratio statistic for proportional-hazards regression models.
The three patients dying in CR from unrelated causes (homicide at 7 months, myocardial infarction secondary to preexisting heart disease at 2.9 years and car accident at 6.2 years) were censored at the time of death for calculating OS and DFS. The three patients developing MDS were considered to have failed (that is, experienced events) at the time of diagnosis of MDS for estimating DFS. Two patients lost to follow-up after having relapsed were considered to have died at the date of the last follow-up for estimating OS.
The disease risk stratification was based upon age, cytogenetics and the time taken to attain CR; 2 a modification of the classification proposed by Hoelzer et al. 20 The following factors were analyzed in Cox proportionalhazards regression models: disease risk (standard versus intermediate versus high), gender, CR transplantation interval (o4 versus X4 months), type of induction therapy (UKALL X or similar versus UKALL XII or similar) and the leukocyte count at presentation (o30 versus X30 Â 10 9 /l). The effect of the intensity of maintenance therapy, in all 100 patients as well as only in the 86 alive and in CR 4 months after transplantation, was examined as follows: 0 versus 1 versus 2 versus 3 agents, and 0/1 agent versus 2/3 agents.
Patient follow-up is current through 10 October 2006 when the median, minimum and maximum follow-up of surviving patients was 11.9, 3.7 and 22.2 years, respectively.
Results
In total, 42 patients had none of the three adverse risk features, 36 had one (29, ageX30 years; 7, time to CR44 weeks) and 19 had two (8, ageX30 years and time to CR44 weeks; 9, high-risk karyotype and ageX30 years, and 2 high-risk karyotype and time to CR44 weeks) and 3 had all three.
Neutrophil recovery to 0.5 Â 10 9 /l was complete and sustained in all patients. Figure 1 shows outcome and current status of all patients. The six patients dying of treatment-related causes had received marrow stem cells and TBI. No deaths occurred among the 65 blood stem cell recipients who received melphalan alone (P ¼ 0.001).
A total of 45 patients relapsed at 0.1-6.9 years. Figure 2a shows the cumulative incidence of relapse. Relapsed disease was confirmed to be identical to the original disease in all cases. No isolated extramedullary recurrence was seen. The outcome of relapsed disease was dismal. Most patients undergoing salvage allogeneic transplantation died of toxicity. The sole survivor had t(9;22) that had become detectable only at the time of relapse following autotransplantation. Figure 2b shows the probability of DFS and OS. Table 2 shows the individual impact of the three major prognostic factors. Figures 2c and d show relapse and DFS by risk stratification.
Three patients, all having received more intensive therapy (UKALL XII or similar) and melphalan with blood stem cells, developed MDS at 1.8, 2.5 and 3.3 years (P ¼ 0.107; Fisher's exact test). Two of them had received all three maintenance chemotherapy agents, and one had received no maintenance therapy because of sluggish hematologic recovery.
Maintenance chemotherapy
In total, 70 patients received 6-MP (at a median of 8 weeks; earliest 2 weeks), 53 received methotrexate (at a median of 20 weeks; earliest 5 weeks) and 40 received vincristineprednisone (at a median of 11 weeks; earliest 3.5 weeks). Post-autograft maintenance chemotherapy in ALL B Sirohi et al Altogether 22 patients received no maintenance chemotherapy at all, 14 received one agent, 43 received two agents and 21 received three agents. The reasons for not getting maintenance chemotherapy were early relapse within 4 months (n ¼ 4), sluggish/incomplete hematologic recovery (n ¼ 10), unknown/patient preference (n ¼ 7) and noncompliance (n ¼ 1). Maintenance chemotherapy was tolerated well. Other than transient myelosuppression requiring dose reduction or temporary cessation of therapy, no other side effects were seen.
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Effect of maintenance chemotherapy
Among the 86 patients alive and well at 120 days, increasing intensity of maintenance chemotherapy (0 versus 1 versus 2 versus 3 agents) was associated with a significantly lower relapse rate (P ¼ 0.021) and higher DFS (P ¼ 0.014). Relapse rate differences were significant when groups getting any versus no chemotherapy were compared (0.025), and when groups getting 0/1 agents versus 2/3 agents were compared (P ¼ 0.005). Similarly, DFS differences were significant when groups getting any versus no chemotherapy were compared (P ¼ 0.012), and when groups getting 0/1 agents versus 2/3 agents were compared (P ¼ 0.002). If the 14 patients relapsing or dying within 4 months are not excluded from the analysis, the beneficial impact of maintenance chemotherapy is artificially exaggerated (data not shown). Table 3 shows the results of the multivariable analysis in patients alive and well on day 120. Low-risk disease and more intense maintenance chemotherapy were associated with lower relapse rates and higher DFS. A longer CR transplant interval was associated with a trend toward better outcome, although the difference did not reach statistical significance. The use of melphalan-TBI as conditioning was associated with a trend toward a lower relapse risk. Figures 3a and b show the effect of the intensity of maintenance chemotherapy on relapse and DFS. These curves have been derived from the Cox model and are plotted at the means of the other covariates.
Cox analysis
Effect of maintenance chemotherapy by risk group
The impact of maintenance chemotherapy (0/1 versus 2/3 agents) by risk group is shown in Table 4 . Receiving more intensive maintenance chemotherapy (0 versus 1 versus 2 versus 3 agents) made a significant beneficial impact on DFS in the low-risk group (P ¼ 0.042); the difference in intermediate-risk patients was borderline (P ¼ 0.10). Maintenance therapy made no difference to patients in the high-risk group (P ¼ 0.59) (details not shown because of small patient numbers). Table 3 Cox analysis of factors affecting relapse and DFS independently among patients alive and disease free on day 120 
Discussion
This large series of adult ALL patients receiving high-dose therapy and autologous HSCT in first remission suggests that post transplant maintenance chemotherapy reduces relapse and improves DFS. The evidence to support this conclusion is as follows: better outcome of patients receiving any maintenance therapy at all compared to those getting none, better outcome of patients receiving two or three drugs compared to those getting none or one and improving outcome with increasing intensity of maintenance chemotherapy (342414none). This benefit was confined to low-and intermediate-risk patients who had none or one of the following adverse risk factors: ageX30 years, 44 weeks to attain CR and high-risk karyotype with t(4;11) or t (9;22) . In addition to its retrospective nature, the obvious weakness of the study is that the ability to tolerate maintenance chemotherapy could have been a surrogate marker for a better quality remission-and a higher likelihood of long-term survival.
The outcome of autologous HSCT was not significantly different from conventional chemotherapy in the French LALA-94 study despite planned post transplant maintenance chemotherapy. 21 In this study, only 52% of the patients actually received maintenance chemotherapy. However, the most important reason for the negative finding is likely the fact that patients with standard-risk disease did not undergo autotransplantation. Standard-risk disease (Group 1 in the study) was defined as all T-cell lineage patients achieving CR after one course of chemotherapy, and B-cell lineage patients without CNS disease, t(9;22), t(4;11), t(1;19), 11q23 rearrangements, presentation leukocyte countX30 and more than one course to CR. This group constituted nearly half of all the patients-and included patients who would have benefited from autograft and maintenance chemotherapy according to our data. Group 2 included patients with highrisk disease excluding t(9;22)-most of whom would not have benefited from maintenance chemotherapy. Group 4 patients consisted those with CNS disease at presentationand would have included patients who were low or intermediate risk using our definition and standard risk by the LALA-94 study definition. Patients in this group who did not have HLA-identical sibling donors underwent autotransplantation followed by maintenance chemotherapy. The 3-year DFS and OS among autografted patients in Group 4 was 47 and 46%. The 5-year DFS rates in the LALA-94 trial were as follows: 35% in Group 1 (standard risk; no transplantation), 30% in Group 2 (high risk; allogeneic HSCT done in 40% and autologous HSCT done in 33%), 20% in Group 3 (Ph þ disease; all to be transplanted) and 41% in Group 4 (CNS disease at presentation; all to be transplanted). The differences in DFS rates between the groups could be interpreted to mean that autologous HSCT was of benefit in non-high-risk patients.
Similarly, the lack of benefit of autologous HSCT in the ECOG 2993/UK MRC ALL XII study 17 may be partly due Table 3 ). (b) Effect of maintenance chemotherapy on DFS in patients alive in remission on day 120 (curves are adjusted for other covariates and have been derived from the Cox model shown in Table 3 ). to lack of maintenance chemotherapy and partly due to patients with relatively high-risk disease undergoing autologous HSCT. We believe that the findings of that study cannot be used to dismiss the potential value of autologous HSCT in ALL. The prognostic model used here is highly predictive of outcome, and can be used to determine appropriate choice of post-induction therapy. Patients with high-risk disease should undergo an allograft from a sibling or an unrelated donor. Those with intermediate-risk disease should undergo allogeneic HSCT if there is an HLAmatched sibling donor available. Further work is required to determine if an allograft from an alternative source (unrelated donor or umbilical cord) or an autograft is the better option if there is no matched sibling donor available for a patient with intermediate-risk disease. 16 Patients with low-risk disease have an excellent outcome following autotransplantation followed by maintenance chemotherapy, and should perhaps be autografted in first remission even if they have an HLA-identical sibling donor. This risk-stratified approach would ensure that patients with a higher likelihood of relapse after autologous HSCT would undergo allogeneic HSCT rather than an autograft.
The reason for not relying on allogeneic HSCT as salvage therapy is the observation in this series that the outcome of patients undergoing a conventional-intensity allograft for post-autograft relapse is dismal. It is possible that the use of a reduced-intensity regimen may result in better outcome. We have shown recently that the outcome of patients undergoing reduced-intensity allogeneic HSCT is not influenced by a prior autograft or the underlying diagnosis. 22 We conclude that autotransplantation followed by maintenance chemotherapy is effective in adult patients with ALL. Future studies evaluating autotransplantation in ALL should be confined to patients with disease that is not high risk, and should incorporate post transplant maintenance chemotherapy.
